Fear and anxiety are often among the first emotions we experience after being diagnosed with pulmonary hypertension (PH) or other rare and complex diseases. Recently, my therapist asked me, “Did you know that naming your fears is the first step in preventing them from controlling your mind?” Despite having…

The European Commission has granted orphan medicinal product designation to Cereno Scientific’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five per 10,000 individuals in the European Union (EU), or…

Liquidia is suing the U.S. Food and Drug Administration (FDA) to challenge a decision that delays the final approval of Yutrepia, its inhaled dry-powder formulation of treprostinil, arguing that the delay unfairly limits patient access to important treatment. Yutrepia was granted tentative approval in 2021 to improve the…

In 2002, three years after my pulmonary hypertension (PH) diagnosis, my family and I made our way to the Pulmonary Hypertension Association’s (PHA) International PH Conference. I have no memories of this gathering, which was the first we’d attended, but it soon became a treasured part of…